Monkeypox Vaccine and Treatment

Global Monkeypox Vaccine and Treatment Market to Reach US$160.5 Million by 2030

The global market for Monkeypox Vaccine and Treatment estimated at US$100.4 Million in the year 2024, is expected to reach US$160.5 Million by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Monkeypox Vaccines, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$107.2 Million by the end of the analysis period. Growth in the Monkeypox Drugs segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$27.4 Million While China is Forecast to Grow at 12.5% CAGR

The Monkeypox Vaccine and Treatment market in the U.S. is estimated at US$27.4 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$34.2 Million by the year 2030 trailing a CAGR of 12.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Global Monkeypox Vaccine and Treatment Market – Key Trends & Drivers Summarized

Why Has the Demand for Monkeypox Vaccines and Treatments Increased Worldwide?

The resurgence of monkeypox in multiple regions across the globe has led to a significant rise in demand for effective vaccines and treatments. Previously considered a rare zoonotic disease confined to Central and West Africa, monkeypox has now spread to numerous countries, prompting the World Health Organization (WHO) and public health agencies to classify it as a growing global health threat. The emergence of human-to-human transmission in urban settings has intensified the urgency for immunization campaigns and antiviral treatments to curb outbreaks. Governments and health organizations have increased funding for vaccine procurement and distribution, particularly for high-risk populations such as immunocompromised individuals, healthcare workers, and those exposed to infected individuals. The need for long-term immunity against potential future outbreaks has also accelerated research into next-generation vaccines with improved efficacy and longer-lasting protection.

What Scientific Advancements Are Shaping the Development of Monkeypox Vaccines and Treatments?

The development of vaccines and therapeutics for monkeypox has been significantly influenced by advances in virology, immunology, and biotechnology. The most widely used vaccines are modified vaccinia virus Ankara (MVA)-based vaccines, originally developed for smallpox but repurposed due to their cross-protective immunity against monkeypox. Next-generation vaccines with improved safety profiles and higher scalability are under development, aiming to provide long-term immunity with fewer side effects. In parallel, antiviral treatments such as tecovirimat (TPOXX), brincidofovir, and cidofovir have been identified as effective options for reducing symptom severity and preventing complications. The integration of monoclonal antibodies into treatment regimens is also being explored to enhance immune response in severe cases. Additionally, mRNA vaccine technology, which revolutionized COVID-19 vaccination, is being studied for its potential application in developing targeted monkeypox vaccines with rapid adaptability to emerging viral mutations. With increasing investment in research and development, the future of monkeypox vaccines and treatments looks promising, offering improved protection and treatment outcomes.

How Are Government Policies and Public Health Strategies Influencing Market Growth?

Governments worldwide have implemented aggressive vaccination strategies and treatment access programs to control the spread of monkeypox, driving market demand for vaccines and therapeutics. Emergency use authorizations (EUAs) and fast-track approvals by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accelerated the availability of vaccines and antiviral drugs. National immunization programs have prioritized at-risk populations, leading to increased vaccine distribution and deployment of stockpiled smallpox vaccines. Public awareness campaigns and community health initiatives have further contributed to vaccination uptake and early treatment adoption. Additionally, funding initiatives by global health organizations, including the WHO and the Coalition for Epidemic Preparedness Innovations (CEPI), have supported large-scale clinical trials and expanded vaccine manufacturing capabilities. As governments continue to prioritize pandemic preparedness, investment in monkeypox vaccine and treatment research is expected to rise.

What Are the Key Factors Driving the Growth of the Monkeypox Vaccine and Treatment Market?

The growth in the monkeypox vaccine and treatment market is driven by several factors, including the rising number of cases, advancements in vaccine development, and strong government intervention. The increased focus on pandemic preparedness and biosecurity measures has led to higher investments in vaccine research and global stockpiling of antiviral drugs. The expansion of production facilities and improvements in vaccine distribution channels are also fueling market growth. Additionally, the shift toward novel vaccine technologies, including mRNA-based formulations, is creating new opportunities for market expansion. The growing adoption of mass immunization programs and proactive testing strategies is further driving demand for monkeypox-related medical interventions. Furthermore, public-private partnerships between pharmaceutical companies and governments are ensuring rapid vaccine rollout and equitable access to treatments. As monkeypox continues to pose a public health threat, the market for vaccines and treatments is expected to witness sustained growth, driven by ongoing research and global vaccination initiatives.

SCOPE OF STUDY:

The report analyzes the Monkeypox Vaccine and Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Monkeypox Vaccines, Monkeypox Drugs); Gender (Male Gender, Female Gender, Other Genders); Administration Route (Oral Administration, Injectable Administration); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Abbott Laboratories
• AstraZeneca plc
• Bavarian Nordic A/S
• BioFactura, Inc.
• BioNTech SE
• Chimerix, Inc.
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• KM Biologics Co., Ltd.
• Merck & Co., Inc.
• Moderna, Inc.
• Novavax, Inc.
• Pfizer Inc.
• Roche Holding AG
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• SIGA Technologies, Inc.
• Tonix Pharmaceuticals Holding Corp.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.